As the most complex class of biologics therapeutics ever developed, cell and gene therapy (CGT) products face unique hurdles in transitioning from research lab processes and R&D to early clinical development manufacturing and then to commercial production and product launch. The key to maintaining a systematic approach in such a diverse class of therapeutics is to develop a control strategy for each of the innovative CGT therapies that will evolve throughout the product life cycle.